Who Supplies Atorvastatin to India from UNITED KINGDOM

To import finished pharmaceutical formulations containing Atorvastatin into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the importer and the product be registered. The importer must obtain an Importer License from the Directorate General of Foreign Trade (DGFT), which requires a valid Importer Exporter Code (IEC). The product must be registered with CDSCO, necessitating the submission of Form 40 or 41, depending on the nature of the product. The registration process includes providing detailed product information, manufacturing site details, and compliance with Good Manufacturing Practices (GMP). The timeline for import drug registration varies but typically ranges from 6 to 12 months, depending on the complexity of the product and the completeness of the application. For formulations under HS Code 30049099, specific requirements include stability data demonstrating compliance with International Council for Harmonisation (ICH) guidelines, labeling in accordance with Indian regulations, and a No Objection Certificate (NOC) from the manufacturer.

Imported finished pharmaceutical formulations containing Atorvastatin must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, including accelerated and long-term studies, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity of the product and ensure it meets all regulatory requirements. The batch testing process typically takes 4 to 6 weeks, depending on the laboratory's workload and the complexity of the product.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. Notably, in April 2025, the CDSCO introduced mandatory import registration and licensing for all imported medicines to prevent the sale of unapproved or illegal drugs in the Indian market. This regulation requires importers to obtain both an Import Registration and License from CDSCO as per the Drugs and Cosmetics Act and associated rules. Additionally, the introduction of the Production Linked Incentive (PLI) scheme has impacted the import of finished formulations by providing incentives to domestic manufacturers, thereby encouraging self-reliance and reducing dependency on imports. These policy changes aim to enhance the quality and safety of imported pharmaceuticals and promote domestic manufacturing capabilities.

India imports finished Atorvastatin formulations primarily due to the demand for patented and branded products that are not manufactured domestically. Specific dosage forms, such as high-potency tablets or combination therapies, may not be produced locally, necessitating imports. While India has a robust pharmaceutical manufacturing sector, certain specialized formulations require sourcing from international markets. The market size for Atorvastatin in India is substantial, with a growing patient population and increasing awareness of cholesterol management. The import dependency is influenced by factors such as the availability of specific formulations, pricing, and the presence of multinational pharmaceutical companies in the Indian market.

The import duty structure for finished pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty of 10.00%, Education Cess of 2.00%, Secondary Higher Education Cess of 1.00%, and Countervailing Duty (CVD) of 6.00%, totaling 17.10%. Additionally, the Integrated Goods and Services Tax (IGST) is applicable, which varies based on the product's classification and the prevailing tax rates. Anti-dumping duties may also be imposed if the government determines that imports are being sold at unfairly low prices, potentially harming domestic industries. Exemption notifications may apply under specific conditions, such as for products used in public health programs or those meeting certain quality standards. The total landed duty percentage is calculated by summing the applicable duties and taxes, which can significantly impact the final cost of imported formulations.

India sources finished Atorvastatin formulations from the United Kingdom due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized formulations not produced domestically. The United Kingdom's pharmaceutical industry is known for its innovation, research and development, and compliance with Good Manufacturing Practices (GMP), making it a reliable supplier. Other suppliers, such as China, Germany, and the United States, also export Atorvastatin formulations to India; however, the United Kingdom's competitive advantage lies in its established trade relations, quality assurance, and the presence of multinational pharmaceutical companies. The United Kingdom's share in the Indian market is significant, reflecting its strong position as a supplier of high-quality pharmaceutical products.

India imports finished Atorvastatin formulations from the United Kingdom due to the availability of patented and branded products that are not manufactured domestically. The United Kingdom offers specialized dosage forms and combination therapies that meet international quality standards, which are essential for effective cholesterol management. Additionally, technology-licensed products from the United Kingdom provide advanced formulations and delivery systems not available in India.